<DOC>
	<DOC>NCT00627848</DOC>
	<brief_summary>The purpose of the study is to investigate the effect of rivastigmine given as an acute dose compared to placebo and after 1 month chronic dosing on fMRI response during a face recognition task. Furthermore, the aim is to investigate whether fMRI response is correlated with long term treatment effect at 6 months and 12 months.</brief_summary>
	<brief_title>Rivastigmine in Mild Alzheimer's Disease, FMRI Study</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Probable Alzheimer's disease according to the NINCDSADRDA criteria mild disease, CDR 1 the clinician is planning to start anticholinesterase treatment cognitive impairment for other reason than Alzheimer's disease severe depression other unstable physical disease medal in body prevention MRI examination, claustrophobia cardiac pacemaker other significant neurologic or psychiatric disease contraindication for anticholinesterase treatment</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Alzheimer's disease</keyword>
	<keyword>fmri</keyword>
	<keyword>face recognition</keyword>
	<keyword>rivastigmine</keyword>
</DOC>